Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma

Table 4

The serum levels of SALL4 of 40 HCCs before and after treatment (pg/mL).

Variables	Median	IQR	𝑃
Before treatment	152.54	103.12–277.26	<0.0001
1 week after treatment	220.42	118.64–371.06
1 month after treatment	80.12	48.07–131.72